CervoMed Inc. 8K

CervoMed reported new Phase 2b, biomarker, imaging, and PK‑PD data for neflamapimod in Dementia with Lewy Bodies that support a 50 mg TID dose and patient selection strategy for a planned Phase 3 trial and highlighted the need for strategic partnering and funding to advance development.

On July 14, 2026, CervoMed Inc. announced at the Alzheimer’s Association International Conference 2026 new clinical, plasma biomarker, imaging, and pharmacokinetic‑pharmacodynamic data for its investigational drug neflamapimod in Dementia with Lewy Bodies, including exploratory analyses from the Phase 2b RewinD‑LB trial that attribute the lack of primary endpoint replication to Alzheimer’s co‑pathology and suboptimal drug exposure, MRI evidence of durable slowing of basal forebrain atrophy and increased basal forebrain connectivity, and results from a separate Phase 2 study showing that an 80 mg BID regimen met safety, tolerability, and PK objectives, all of which support selection of a 50 mg TID dose and define the patient population for a planned Phase 3 DLB trial for which the company has regulatory alignment and is seeking a strategic partner and funding.

Filing Facts

CIK

1053691

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-023538

Alert Tier

6